Myriam Chalabi

Jun 27, 2024 | dailyreporter.esmo.org | Myriam Chalabi

Colorectal cancer (CRC), one of the most prevalent cancers globally, can be classified into two groups based on its ability to repair DNA microsatellite damage. Tumours that are mismatch repair-deficient and have high levels of microsatellite instability (MSI) have shown remarkable responses to immunotherapy, particularly checkpoint inhibitors.

Feb 21, 2023 | ejso.com | Johanna van Sandick |Jolanda van Dieren |Marieke Vollebergh |Myriam Chalabi

Background: In gastric cancer (GC) patients HER2 is the only widely used predictive biomarker implemented in guidelines for metastatic patients. With recent successes in immunotherapy (IT) in upper GI malignancies, mismatch repair (MMR), Epstein-Barr Virus (EBV) testing and PD-L1 CPS (combined positive score) have become more important. However, most data on immunotherapy and biomarkers in gastric cancer originate from retrospective studies on selected patient populations.